"Regarding options for twice-infected covid patients, Humanigen has developed a lenzilumab/w/traditional vaccine/w/ anti-viral cocktail, and polyclonal antibodies, that could prove to be an effective preventative or treatment for those patients. Please evaluate this option."
I couldn't say more due to space limitations for Twitter replies. If he replies to me, I will send him links to additional data, unless Geert asks management for additional information.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.